Caris Life Sciences, Inc.
CAI
$24.03
-$0.79-3.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 137.68% | 112.43% | 75.85% | -- | -- |
| Total Depreciation and Amortization | -37.18% | -46.06% | -53.76% | -- | -- |
| Total Amortization of Deferred Charges | -55.40% | 81.50% | 81.00% | -- | -- |
| Total Other Non-Cash Items | -10.97% | 195.65% | 1,421.67% | -- | -- |
| Change in Net Operating Assets | -430.91% | -162.05% | -13.97% | -- | -- |
| Cash from Operations | 227.31% | 172.73% | 133.91% | -- | -- |
| Capital Expenditure | -444.39% | -154.53% | -92.56% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,666.37% | -154.53% | -130.72% | -- | -- |
| Total Debt Issued | 1,312.17% | -- | -86.07% | -- | -- |
| Total Debt Repaid | -446,549.45% | -25.25% | 32.48% | -- | -- |
| Issuance of Common Stock | -98.19% | 19,347.42% | 34,938.95% | -- | -- |
| Repurchase of Common Stock | -2,499.11% | -84,890.91% | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -285.13% | -14.69% | -35.98% | -- | -- |
| Cash from Financing | -107.87% | 45,136.76% | 232.01% | -- | -- |
| Foreign Exchange rate Adjustments | -105.00% | 11,700.00% | 3,350.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.52% | 474.32% | 9,026.22% | -- | -- |